"Nov. 2, 2012 -- Safety steps taken in the wake of the fungal meningitis outbreak have worsened drug shortages, raising questions about whether the U.S. must choose between the safety and the availability of crucial medicines.
- Clinician Information:
Alfenta Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Alfenta (alfentanil hydrochloride) Injection is an opioid analgesic used before and/or during surgery. This medication is available in generic form. Common side effects include slowed breathing, muscular rigidity, low blood oxygen, nausea, low blood pressure, vomiting, itching, confusion, sleepiness, and agitation.
The dosage of Alfenta should be individualized for each patient according to body weight, physical status, underlying condition, use of other drugs, and type and duration of surgical procedure and anesthesia. Alfenta may interact with barbiturates, tranquilizers, opioids, inhalation general anesthetics, or cimetidine. Tell your doctor all medications and supplements you use. During pregnancy, Alfenta should be used only if prescribed. Caution should be used if nursing; consult your doctor before breastfeeding. Withdrawal symptoms may occur if you suddenly stop taking this medication.
Our Alfenta (alfentanil hydrochloride) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Alfenta FDA Prescribing Information: Side Effects
The most common adverse reactions of opioids are respiratory depression and skeletal muscle rigidity, particularly of the truncal muscles. ALFENTA (alfenta (alfenta (alfentanil) nil) nil) may produce muscular rigidity that involves the skeletal muscles of the neck and extremities. See CLINICAL PHARMACOLOGY, WARNINGS, and PRECAUTIONS on the management of respiratory depression and skeletal muscle rigidity.
The adverse experience profile from 696 patients receiving ALFENTA (alfenta (alfenta (alfentanil) nil) nil) for Monitored Anesthesia Care (MAC) is similar to the profile established with ALFENTA (alfenta (alfenta (alfentanil) nil) nil) during general anesthesia. Respiratory events reported during MAC included hypoxia, apnea, and bradypnea. Other adverse events reported by patients receiving ALFENTA (alfenta (alfenta (alfentanil) nil) nil) for MAC, in order of decreasing frequency, were nausea, hypotension, vomiting, pruritus, confusion, somnolence and agitation.
The following adverse reaction information is derived from controlled and open clinical trials in 785 patients who received intravenous ALFENTA (alfenta (alfenta (alfentanil) nil) nil) during induction and maintenance of general anesthesia. The controlled trials included treatment comparisons with fentanyl, thiopental sodium, enflurane, saline placebo and halothane. The incidence of certain side effects is influenced by the type of use, e.g., chest wall rigidity has a higher reported incidence in clinical trials of alfenta (alfenta (alfenta (alfentanil) nil) nil) nil induction, and by the type of surgery, e.g., nausea and vomiting have a higher reported incidence in patients undergoing gynecologic surgery. The overall reports of nausea and vomiting with ALFENTA (alfenta (alfenta (alfentanil) nil) nil) were comparable to fentanyl.
Incidence Greater than 1% - Probably Causally Related (Derived from clinical trials)
Gastrointestinal: nausea (28%), vomiting (18%)
Cardiovascular: arrhythmia, bradycardia (14%), hypertension (18%), hypotension (10%), tachycardia (12%)
Musculoskeletal: chest wall rigidity (17%), skeletal muscle movements*
Respiratory: apnea*, postoperative respiratory depression
Central Nervous System: blurred vision, dizziness*, sleepiness/postoperative sedation
*Incidence 3% to 9%
All others 1% to 3%
Incidence Less than 1% - Probably Causally Related (Derived from clinical trials)
Adverse events reported in post-marketing surveillance, not seen in clinical trials, are italicized.
Body as a whole: anaphylaxis
Central Nervous System: headache*, myoclonic movements, postoperative confusion*, postoperative euphoria*, shivering*
Dermatological: itching*, urticaria*
Injection Site: pain*
Musculoskeletal: skeletal muscle rigidity of neck and extremities
Respiratory: bronchospasm, hypercarbia*, laryngospasm*
*Incidence 0.3% to 1%
Drug Abuse And Dependence
ALFENTA (alfenta (alfenta (alfenta (alfentanil) nil) nil) nil hydrochloride) is a Schedule II controlled drug substance that can produce drug dependence of the morphine type and therefore has the potential for being abused.
Opioid analgesics have been associated with abuse and dependence in health care providers and others with ready access to such drugs. ALFENTA (alfenta (alfenta (alfentanil) nil) nil) should be handled accordingly.
Read the entire FDA prescribing information for Alfenta (Alfentanil for Injection) »
Additional Alfenta Information
- Alfenta Drug Interactions Center: alfentanil inj
- Alfenta Side Effects Center
- Alfenta FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Chronic Pain/Back Pain
Find tips and advances in treatment.